Comparative clinical efficacy and neurobiological correlates of true-vs-sham ECT in patients with clozapine-resistant/intolerant schizophrenia

Department of Psychiatry National Institute of Mental Health and Neuro Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Schizophrenia Diagnosis (DSM-5);
•2.Right-Handedness (Edinburgh Handedness Inventory);
•3.Inadequate response to at least two adequate trials of antipsychotic (other than clozapine);
•4.Received an adequate trial of clozapine or discontinued/unable to receive an adequate dose of clozapine due to poor tolerability;
•5.At least 6-weeks stable antipsychotic dosage;
•6.Score of 4 or more on one or more of items 4 (Conceptual disorganization), 11 (suspiciousness), 12 (hallucinatory behaviour) or 15 (unusual thought content) in Brief psychiatric rating scale OR a score of 4 or more on all the above items combined OR presence of at least 2 items in Bush Francis Catatonia Rating Scale screener
•7.Prior consent by the patient for receiving ECT as treatment (obtained by the treating clinical team);
•8.Capacity to consent for research studies as per the assessment using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC);
•9.Written informed consent.

•1.Severe general medical/neurological comorbidity that precludes ECT or has an effect on cognition and behaviour
•2.Received ECT in the past
•3.Score of > 6 on the Calgary Depression Rating Scale
•4.Suicidal risk / any psychiatric emergency
•5.Pregnancy / Post-Partum
•6.Current psychoactive substance dependence (except caffeine or nicotine)
•7.Co-morbid neurological/medical disease that can affect the brain structure/function
•8.Any Contraindication for Magnetic Resonance Imaging
•9.Any Contraindication for Transcranial Magnetic Stimulation
•10.Any Contraindication for Transcranial Direct Current Stimulation

发起方

Department of Psychiatry National Institute of Mental Health and Neuro Sciences